| GTO ID | GTC3502 |
| Trial ID | NCT05934448 |
| Disease | Primary Mediastinal Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | Jennifer Crombie, MD |
| Other ID(s) | 23-179 |
| Cohort 1 | |||||||||
|
|||||||||